Prescribing Under Pressure: History and Legal Insights Into Boxed Warnings for Psychotropic Drugs

A boxed warning, or "black box" warning, represents the US Food and Drug Administration's most serious cautionary statement for prescription drugs. These warnings communicate clinically significant risks that may alter prescribing decisions, patient consent, and medicolegal responsibility. This narrative review explores the regulatory history, creation, and modification of boxed warnings, emphasizing their role in psychopharmacology. Using the case of varenicline (Chantix) as a focal example, we trace how emerging postmarketing data led to the implementation and subsequent removal of its boxed warning. We then summarize major boxed warnings across psychotropic classes, highlighting practical implications for prescribing, documentation, and informed consent. Finally, we discuss strategies for integrating boxed warning awareness into clinical decision-making and patient communication. Boxed warnings serve not merely as restrictions but as instruments of safety, vigilance, and shared decision-making that enhance the quality of psychiatric care.